Whale Large Capital
  • Politics
  • World News
  • Business
  • Investing
  • Politics
  • World News
  • Business
  • Investing

Whale Large Capital

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
World’s oldest man, John Tinniswood, dies aged 112
next post
Spanish retailer Mango to open 60 new U.S. stores as it looks to elevate the brand

You may also like

Republicans scrap deal in ‘big, beautiful bill’ to...

July 1, 2025

Trump says ‘I don’t care when you vote’...

October 15, 2024

Supreme Court to hear case on LGBTQ-themed storybooks...

April 22, 2025

HHS probing hospital over firing of nurse who...

April 18, 2025

RFK Jr. says he plans to also meet...

December 17, 2024

Meet the young team of software engineers slashing...

February 5, 2025

‘Dr. Strangelove with a mustache’: Bolton blasted for...

August 26, 2025

JOSH HAMMER: Trial lawyer lawfare vs. Trump’s policy...

September 20, 2025

US will know in ‘matter of weeks’ if...

April 4, 2025

Judge blocks Trump from placing 2,200 USAID workers...

February 8, 2025

    Subscribe today to receive exclusive access to all our retirement secrets and income strategies, including special financial news and updates from our experts. From time to time, our newsletters feature valuable insights and analysis on the latest financial trends. Don't miss out on these exclusive updates – join our subscription to stay informed!


    By opting in you agree to receive emails from us. Your information is secure and your privacy is protected.



    Latest

    • President Donald Trump commutes former New York GOP Rep. George Santos’ prison sentence

      October 17, 2025
    • ‘Democrat shutdown’ will next jeopardize US nuclear stockpile with imminent furloughs: White House

      October 17, 2025
    • Supreme Court sets date to hear FTC Slaughter case in test of Trump’s firing powers

      October 17, 2025
    • ‘Time for a change’: Outside 30 Rock, New Yorkers trade chants and arguments during tense mayoral showdown

      October 17, 2025
    • Andrea Bocelli gives Trump impromptu Oval Office performance during White House visit

      October 17, 2025
    • Giorgio Armani group names longtime executive Giuseppe Marsocci as CEO

      October 17, 2025

    Categories

    • Business (814)
    • Investing (661)
    • Politics (5,986)
    • World News (3,213)
    • Terms & Conditions
    • Privacy Policy
    • Contact us
    • About us

    Disclaimer: WhaleLargeCapital.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 WhaleLargeCapital.com | All Rights Reserved